The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: A review

Chris Cobos, José A. Figueroa, Leonardo Mirandola, Michela Colombo, Gabby Summers, Alejandro Figueroa, Amardeep Aulakh, Venu Konala, Rashmi Verma, Jehanzeb Riaz, Raymond Wade, Charles Saadeh, Rakhshanda L. Rahman, Apurva Pandey, Saba Radhi, Diane D. Nguyen, Marjorie Jenkins, Maurizio Chiriva-Internati, Everardo Cobos

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela.

Original languageEnglish (US)
Pages (from-to)383-401
Number of pages19
JournalInternational Reviews of Immunology
Volume33
Issue number5
DOIs
StatePublished - Sep 3 2014

Fingerprint

Papillomaviridae
Virus Diseases
Immunotherapy
Neoplasms
Papillomavirus Vaccines
Immunization Programs

Keywords

  • Anogenital cancer
  • Cervical cancer
  • Gardasil
  • Head and neck squamous cell carcinoma
  • Vevarix

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy : A review. / Cobos, Chris; Figueroa, José A.; Mirandola, Leonardo; Colombo, Michela; Summers, Gabby; Figueroa, Alejandro; Aulakh, Amardeep; Konala, Venu; Verma, Rashmi; Riaz, Jehanzeb; Wade, Raymond; Saadeh, Charles; Rahman, Rakhshanda L.; Pandey, Apurva; Radhi, Saba; Nguyen, Diane D.; Jenkins, Marjorie; Chiriva-Internati, Maurizio; Cobos, Everardo.

In: International Reviews of Immunology, Vol. 33, No. 5, 03.09.2014, p. 383-401.

Research output: Contribution to journalArticle

Cobos, C, Figueroa, JA, Mirandola, L, Colombo, M, Summers, G, Figueroa, A, Aulakh, A, Konala, V, Verma, R, Riaz, J, Wade, R, Saadeh, C, Rahman, RL, Pandey, A, Radhi, S, Nguyen, DD, Jenkins, M, Chiriva-Internati, M & Cobos, E 2014, 'The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: A review', International Reviews of Immunology, vol. 33, no. 5, pp. 383-401. https://doi.org/10.3109/08830185.2014.911857
Cobos, Chris ; Figueroa, José A. ; Mirandola, Leonardo ; Colombo, Michela ; Summers, Gabby ; Figueroa, Alejandro ; Aulakh, Amardeep ; Konala, Venu ; Verma, Rashmi ; Riaz, Jehanzeb ; Wade, Raymond ; Saadeh, Charles ; Rahman, Rakhshanda L. ; Pandey, Apurva ; Radhi, Saba ; Nguyen, Diane D. ; Jenkins, Marjorie ; Chiriva-Internati, Maurizio ; Cobos, Everardo. / The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy : A review. In: International Reviews of Immunology. 2014 ; Vol. 33, No. 5. pp. 383-401.
@article{fe9f608573e248df836a6c009734c46c,
title = "The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: A review",
abstract = "Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela.",
keywords = "Anogenital cancer, Cervical cancer, Gardasil, Head and neck squamous cell carcinoma, Vevarix",
author = "Chris Cobos and Figueroa, {Jos{\'e} A.} and Leonardo Mirandola and Michela Colombo and Gabby Summers and Alejandro Figueroa and Amardeep Aulakh and Venu Konala and Rashmi Verma and Jehanzeb Riaz and Raymond Wade and Charles Saadeh and Rahman, {Rakhshanda L.} and Apurva Pandey and Saba Radhi and Nguyen, {Diane D.} and Marjorie Jenkins and Maurizio Chiriva-Internati and Everardo Cobos",
year = "2014",
month = "9",
day = "3",
doi = "10.3109/08830185.2014.911857",
language = "English (US)",
volume = "33",
pages = "383--401",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The role of Human Papilloma Virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy

T2 - A review

AU - Cobos, Chris

AU - Figueroa, José A.

AU - Mirandola, Leonardo

AU - Colombo, Michela

AU - Summers, Gabby

AU - Figueroa, Alejandro

AU - Aulakh, Amardeep

AU - Konala, Venu

AU - Verma, Rashmi

AU - Riaz, Jehanzeb

AU - Wade, Raymond

AU - Saadeh, Charles

AU - Rahman, Rakhshanda L.

AU - Pandey, Apurva

AU - Radhi, Saba

AU - Nguyen, Diane D.

AU - Jenkins, Marjorie

AU - Chiriva-Internati, Maurizio

AU - Cobos, Everardo

PY - 2014/9/3

Y1 - 2014/9/3

N2 - Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela.

AB - Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela.

KW - Anogenital cancer

KW - Cervical cancer

KW - Gardasil

KW - Head and neck squamous cell carcinoma

KW - Vevarix

UR - http://www.scopus.com/inward/record.url?scp=84907852437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907852437&partnerID=8YFLogxK

U2 - 10.3109/08830185.2014.911857

DO - 10.3109/08830185.2014.911857

M3 - Article

C2 - 24811210

AN - SCOPUS:84907852437

VL - 33

SP - 383

EP - 401

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 5

ER -